Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.

  • Del Fresno, Carlos
  • García-Arriaza, Juan
  • Martínez-Cano, Sarai
  • Heras-Murillo, Ignacio
  • Jarit-Cabanillas, Aitor
  • Amores-Iniesta, Joaquin
  • Brandi, Paola
  • Dunphy, Gillian
  • Suay-Corredera, Carmen
  • Pricolo, Maria Rosaria
  • Vicente, Natalia
  • López-Perrote, Andrés
  • Cabezudo, Sofía
  • González-Corpas, Ana
  • Llorca, Oscar
  • Alegre-Cebollada, Jorge
  • Garaigorta, Urtzi
  • Gastaminza, Pablo
  • Esteban, Mariano
  • Sancho, David
COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inactivated bacteria, that has shown clinical efficacy against recurrent viral respiratory infections. Herein, we show that the prophylactic intranasal administration of this immunotherapy confers heterologous protection against SARS-CoV-2 infection in susceptible K18-hACE2 mice. Furthermore, in C57BL/6 mice, prophylactic administration of MV130 improves the immunogenicity of two different COVID-19 vaccine formulations targeting the SARS-CoV-2 spike (S) protein, inoculated either intramuscularly or intranasally. Independently of the vaccine candidate and vaccination route used, intranasal prophylaxis with MV130 boosted S-specific responses, including CD8+-T cell activation and the production of S-specific mucosal IgA antibodies. Therefore, the bacterial mucosal immunotherapy MV130 protects against SARS-CoV-2 infection and improves COVID-19 vaccines immunogenicity.